A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol

BACKGROUND: The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to resection or systemic therapies. Prolonged survival has been observed following resection or stereotactic ablative body radiotherapy (SABR). Immunotherapy combinations hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Pryor, David, Bressel, Mathias, Lawrentschuk, Nathan, Tran, Ben, Mooi, Jennifer, Lewin, Jeremy, Azad, Arun, Colyer, Duncan, Neha, Nitika, Shaw, Mark, Chander, Sarat, Neeson, Paul, Moon, Daniel, Cuff, Katharine, Wood, Simon, Murphy, Declan G., Sandhu, Shahneen, Loi, Sherene, Siva, Shankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807247/
https://www.ncbi.nlm.nih.gov/pubmed/33490707
http://dx.doi.org/10.1016/j.conctc.2021.100703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807247/
https://www.ncbi.nlm.nih.gov/pubmed/33490707
http://dx.doi.org/10.1016/j.conctc.2021.100703

Ejemplares similares